Location: Penn State Cancer Institute
For people with an aggressive form of non-Hodgkin lymphoma, treatments can be limited. Enter a new treatment called Yescarta. Yescarta, or axicabtagene ciloleucel, can be nothing short of “miraculous” for these patients.
From aging to cancer—with quite a bit in between—Katherine Aird, assistant professor of Cellular and Molecular Physiology at Penn State College of Medicine, and her team have a whole world of research opportunities in front of them.
As if it weren't hard enough to fight cancer as a kid, childhood cancer survivors are at a higher risk of developing physical and emotional difficulties once their treatment is complete. We learn more about these challenges and how professionals at Penn State Children’s Hospital navigate them from Dr. Smita Dandekar, director of the Pediatric Cancer Survivorship Clinic, and Amanda Musser, Four Diamonds social worker.
A team of researchers has developed a new framework that can combine three existing methods of finding mutations -- or structural variants -- in the DNA of cancer cells into a single, more complete picture.